Pyelonephritis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 17: | Line 17: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | |||
[[Category:Neurology]] | |||
Latest revision as of 23:54, 29 July 2020
|
Pyelonephritis Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pyelonephritis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Pyelonephritis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pyelonephritis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
According to an estimate the mean cost of diagnosing and managing a patient with urinary tract infection including pyelonephritis is more than 229 pounds per year. Hyaluronan therapy given long term cuts down the cost of multiple pretreatments as it prevents recurrence of a urinary tract infection.[1][2]
Cost Effectiveness of therapies
- Hyaluronan is very cost effective in the long run when compared with all alternative treatments, despite initial high costs.[1]
- Amoxicillin is almost two times cheaper than aminoglycosides when used in the treatment of uncomplicated cystitis and pyelonephritis.[2]
- First and Second generation cephalosporins are considered to be cost effective in treating lower urinary tract infections empirically.[3]
- Gentamicin is suggested as an cost effective therapy for treatment of pyelonephritis during pregnancy.[3]
- The use of fluoroquinolone and nitrofurantoin is not cost effective.[4]
References
- ↑ 1.0 1.1 Riedl C, Engelhardt P, Schwarz B (2013). "Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines". Clin Drug Investig. 33 (10): 737–42. doi:10.1007/s40261-013-0119-4. PMID 23921624.
- ↑ 2.0 2.1 Ciani O, Grassi D, Tarricone R (2013). "An economic perspective on urinary tract infection: the "costs of resignation"". Clin Drug Investig. 33 (4): 255–61. doi:10.1007/s40261-013-0069-x. PMID 23475540.
- ↑ 3.0 3.1 Jakobi P, Goldstick O, Finkelstein R, Itzkovitz-Eldor J (1998). "[Empirical treatment of urinary tract infections in the delivery room--findings and desires]". Harefuah. 135 (9): 344–7, 408. PMID 10911441.
- ↑ Huang ES, Stafford RS (2002). "National patterns in the treatment of urinary tract infections in women by ambulatory care physicians". Arch Intern Med. 162 (1): 41–7. PMID 11784218.